ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.